Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsStem CellsTransplantation ChimeraBone Marrow TransplantationTissue DonorsTreatment OutcomeMyeloablative AgonistsBusulfanGraft vs Leukemia EffectRecurrenceGraft SurvivalHistocompatibility TestingRemission InductionCord Blood Stem Cell TransplantationVidarabineGraft vs Tumor EffectRetrospective StudiesWhole-Body IrradiationLeukemiaHistocompatibilityLiver TransplantationImmunosuppressive AgentsMultiple MyelomaLeukemia, Myeloid, AcuteHematopoietic Stem Cell MobilizationLymphocyte TransfusionCombined Modality TherapyChimerismSiblingsMyelodysplastic SyndromesDisease-Free SurvivalAntigens, CD34Survival RateSurvival AnalysisCytomegalovirus InfectionsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHepatic Veno-Occlusive DiseaseMesenchymal Stem Cell TransplantationSalvage TherapyTime FactorsMelphalanAntilymphocyte SerumPrecursor Cell Lymphoblastic Leukemia-LymphomaLymphocyte DepletionHematopoiesisHematologic DiseasesHLA AntigensMinor Histocompatibility AntigensCell TransplantationCyclophosphamideEmbryonic Stem CellsKidney TransplantationCell DifferentiationNeoplasm, ResidualTransplantation ImmunologyAntineoplastic Combined Chemotherapy ProtocolsAdult Stem CellsVirus ActivationBone Marrow CellsT-LymphocytesAnemia, AplasticFollow-Up StudiesAcute DiseaseIncidenceCytomegalovirusFlow CytometryStem Cell NichePrognosisGranulocyte Colony-Stimulating FactorImmunosuppressionTransplantation, IsogeneicUnrelated DonorsImmunocompromised HostCell LineageLymphoproliferative DisordersGraft RejectionBone MarrowPrimary MyelofibrosisCytarabineLeukemia, MyeloidMice, Inbred C57BLLymphoma, Non-HodgkinOpportunistic InfectionsPluripotent Stem CellsHeart TransplantationAntineoplastic AgentsHodgkin DiseaseInfectionRisk FactorsSevere Combined ImmunodeficiencyMesenchymal Stromal CellsCells, Cultured